Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + sintilimab + XELOX in unresectable advanced hepatocellular carcinoma
ChiCTR2500114008Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib, sintilimab and Capecitabine + oxaliplatin in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
lenvatinibsintilimabCapecitabine + oxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500114008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114008.